SynBio

SynBio
Industry Biotech Research and Pharmaceuticals
Founded August 2011 (2011-08)
Headquarters Moscow, Russia
Owner RUSNANO, HSCI, FDS Pharma, Dmitry Genkin, Cryonix, and Pharmsynthez
Website www.synbio-pharma.com

SynBio is a long-term project started in 2011 with the goal of creating innovative medicines, including what are known as Biobetters. This project is a collaborative effort of several Russian and international pharmaceutical companies. The largest private participant of SynBio is the Human Stem Cells Institute (HSCI), a leading Russian biotech company, and the Russian Corporation of Nanotechnologies (RUSNANO) is a key investor.[1] The project is a significant example of international cooperation between researchers in Russia, England, and Germany. Special project company SynBio LLC is headquartered in Moscow.[2]

Currently, SynBio LLC is developing nine drugs based on three biotechnology platforms (Histone, PolyXen and Gemacell) for the treatment of liver disease, cardiovascular disease, acute leukemia, growth hormone deficiency and diabetes mellitus.[3][4]

The SynBio project also entails the creation of modern production facilities. These facilities will be dedicated to the manufacturing of the company’s pharmaceutical substances and market-ready medicines once they have successfully undergone clinical testing.[5]

Research and Development Centers

References

  1. "Russian firms set upset up $113 million biotech venture". Pharma Times Online. August 9, 2011.
  2. "About Us". SynBio.
  3. "Russian Firms Establish Joint Biotech Venture". Pharmaceutical-Technology. 10 August 2011.
  4. "Russia biotech: Innovation drive". The Economist Intelligence Unit. August 16, 2011.
  5. "В Ленобласти будут производить лекарства против болезни Альцгеймера". Делового Петербурга. 5.8.2011. Check date values in: |date= (help)
  6. "Xenetic Biosciences".
  7. "Symbiotech".
  8. "HSCI".
This article is issued from Wikipedia - version of the 4/25/2013. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.